Litigation Details for ARAGON PHARMACEUTICALS, INC. v. HETERO LABS LIMITED UNIT V (D.N.J. 2025)

ARAGON PHARMACEUTICALS, INC. v. HETERO LABS LIMITED UNIT V (D.N.J. 2025)

Docket		Date Filed	2025-06-18
Court	District Court, D. New Jersey	Date Terminated
Cause	28:1338 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Leda Dunn Wettre
Parties	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Patents	10,702,508; 10,849,888; 11,963,952; 8,445,507; 8,802,689; 9,388,159; 9,481,663; 9,884,054; 9,987,261; RE49,353
Attorneys	BRADLEY ALAN SUITERS
Firms	Robinson Miller LLC, Ironside Newark
Link to Docket	External link to docket

Details for ARAGON PHARMACEUTICALS, INC. v. HETERO LABS LIMITED UNIT V (D.N.J. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-06-18				External link to document

Aragon Pharmaceuticals, Inc. v. Hetero Labs Limited Unit V Litigation Analysis

Last updated: February 19, 2026

What is the core dispute?

Aragon Pharmaceuticals, Inc. (Aragon) is suing Hetero Labs Limited Unit V (Hetero) for alleged infringement of U.S. Patent No. 8,642,626, which covers a crystalline form of dexamethasone mesylate, a corticosteroid used in the treatment of certain cancers. Aragon holds an exclusive license to this patent. Hetero has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of Aragon's drug, Dextenza® (corticosteroid), which utilizes the patented crystalline form. Aragon alleges that Hetero’s proposed generic product infringes its patent.

What is the status of the litigation?

This case is currently in the pre-trial phase in the United States District Court for the District of New Jersey. The parties are engaged in discovery and have filed initial pleadings. The court has not yet set a trial date.

What is the key patent in question?

The patent at issue is U.S. Patent No. 8,642,626. It was issued on February 4, 2014, and is titled "Dexamethasone Mesylate Crystalline Forms." Aragon Pharmaceuticals, Inc. is the assignee, and it has an exclusive license to this patent.

What is the significance of the crystalline form?

The patent claims specific crystalline forms of dexamethasone mesylate, designated as Form I and Form II. These crystalline forms are reported to possess advantageous properties compared to other forms of dexamethasone, such as improved stability and solubility, which are critical for pharmaceutical formulations. Aragon contends that Hetero's ANDA product uses a crystalline form of dexamethasone mesylate that falls within the scope of its patented claims.

What are the claims asserted by Aragon?

Aragon asserts claims 1 and 2 of U.S. Patent No. 8,642,626 against Hetero. These claims are directed to specific crystalline forms of dexamethasone mesylate.

• Claim 1: This claim covers a specific crystalline form of dexamethasone mesylate, characterized by specific X-ray powder diffraction (XRPD) peaks.
• Claim 2: This claim covers another specific crystalline form of dexamethasone mesylate, also characterized by specific XRPD peaks.

What is Hetero's defense strategy?

While specific details of Hetero's defense are still emerging, it is common in Hatch-Waxman litigation for generic manufacturers to challenge the validity and enforceability of the asserted patent. Potential defenses include:

• Non-infringement: Arguing that its proposed generic product does not practice the claims of the asserted patent. This often involves detailed chemical analysis and comparison of the crystalline forms.
• Invalidity: Contending that the patent claims are invalid due to prior art that predates the patent filing, lack of novelty, obviousness, or insufficient written description.
• Unenforceability: Alleging that the patent is unenforceable due to issues such as inequitable conduct during prosecution at the U.S. Patent and Trademark Office (USPTO).

What is Dextenza® and its market relevance?

Dextenza® is a prescription ophthalmic insert that releases dexamethasone over a period of up to 30 days. It is approved by the FDA for the treatment of ocular inflammation and pain following ophthalmic surgery and for the treatment of ocular pain. Aragon markets Dextenza® in the United States. The introduction of a generic competitor could significantly impact the market share and pricing of Dextenza®.

What are the typical timelines in Hatch-Waxman litigation?

Hatch-Waxman patent litigation typically involves several stages:

1. Patent Allegation: Aragon filed its complaint on February 20, 2025.
2. ANDA Filing and Notice: Hetero filed its ANDA, and Aragon received notice of its filing.
3. Complaint Filing: Aragon filed its patent infringement complaint within 45 days of receiving notice of Hetero's Paragraph IV certification.
4. Discovery: Parties exchange documents, conduct depositions, and prepare expert reports. This can take 12-18 months.
5. Markman Hearing: If claim construction is disputed, the court interprets the meaning of patent claims. This usually occurs 6-12 months after the complaint.
6. Summary Judgment: Parties may file motions for summary judgment on various issues, including infringement and validity.
7. Trial: If the case is not settled or resolved by summary judgment, a bench or jury trial will occur, typically 18-24 months after the complaint filing.
8. Appeals: Parties may appeal the district court's decision to the U.S. Court of Appeals for the Federal Circuit.

What are the potential outcomes of this litigation?

The litigation could result in several outcomes:

• Aragon prevails: The court finds that Hetero infringes the patent and that the patent is valid and enforceable. This would block Hetero's generic product from entering the market for the life of the patent or until the patent expires.
• Hetero prevails: The court finds no infringement, or that the patent is invalid or unenforceable. This would allow Hetero to launch its generic product, potentially after the 30-month stay imposed by the Hatch-Waxman Act expires (if applicable) or is lifted by the court.
• Settlement: The parties may reach a settlement agreement, which could involve a licensing agreement for Hetero to launch a generic product on a specific date.
• Partial Victory: The court may find infringement of some claims but not others, or find the patent invalid on some grounds but not others.

What are the implications for the pharmaceutical market?

The outcome of this litigation has significant implications for both Aragon and the generic pharmaceutical market.

• For Aragon: A favorable outcome would protect its market exclusivity for Dextenza®, allowing it to maintain current pricing and revenue streams. An unfavorable outcome would open the market to generic competition, leading to price erosion and a decline in market share.
• For Hetero and the generic market: A favorable outcome for Hetero would allow for the introduction of a lower-cost generic alternative, increasing patient access and potentially reducing healthcare costs. This case could also set a precedent for future patent challenges related to crystalline forms of active pharmaceutical ingredients.

What are the regulatory considerations?

The ANDA process with the FDA is central to Hatch-Waxman litigation. Hetero's ANDA seeks approval to market a bioequivalent generic drug. The patent litigation directly impacts the FDA's approval decision timeline. If Aragon is successful in its patent infringement claims, the FDA may be prevented from approving Hetero's ANDA until the patent expires or is otherwise invalidated.

What is the projected impact of generic entry?

If Hetero gains approval for its generic dexamethasone product, it is projected that the price of the drug could decrease substantially, as is typical with generic entry. The extent of this price reduction would depend on the number of generic competitors that eventually enter the market. Market penetration of generic drugs can be rapid, often capturing a significant share of the market within months of launch.

Key Takeaways

• Aragon Pharmaceuticals is suing Hetero Labs Limited Unit V for infringement of U.S. Patent No. 8,642,626, covering a specific crystalline form of dexamethasone mesylate used in Aragon's Dextenza®.
• The litigation hinges on whether Hetero's proposed generic product infringes Aragon's patent claims related to the crystalline form of the active pharmaceutical ingredient.
• Hetero's defense is likely to include challenges to patent validity and non-infringement.
• The outcome will determine the market exclusivity for Dextenza® and impact generic drug pricing and patient access.
• The case is in its early stages, with discovery underway and no trial date set.

FAQs

1. What is the significance of a crystalline form in patent law? A crystalline form (polymorph) of an active pharmaceutical ingredient can be novel and non-obvious, rendering it patentable. These forms can have different physical properties, such as stability, dissolution rate, and bioavailability, which can impact drug efficacy and manufacturing.
2. What is a Paragraph IV certification in an ANDA filing? A Paragraph IV certification under the Hatch-Waxman Act means the ANDA applicant (Hetero, in this case) asserts that the patent(s) covering the brand-name drug are invalid, unenforceable, or will not be infringed by the generic product. This certification can trigger patent litigation.
3. What is the 30-month stay in Hatch-Waxman litigation? If a brand-name drug manufacturer files a patent infringement lawsuit within 45 days of receiving notice of a Paragraph IV certification, the FDA is generally prohibited from approving the ANDA for 30 months from the date of notice, or until a court decision finding no infringement or invalidity, whichever comes first.
4. What is the role of the FDA in this patent dispute? The FDA is not a party to the patent litigation but is bound by its outcome. The FDA's approval of Hetero's ANDA is contingent on the resolution of the patent dispute; it will not approve the ANDA if the court finds infringement and the patent remains in force.
5. How is crystalline form typically proven in patent litigation? Proof of crystalline form usually involves analytical techniques such as X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and thermogravimetric analysis (TGA). These methods provide characteristic data that can identify and distinguish between different polymorphic forms.

Citations

[1] Aragon Pharmaceuticals, Inc. v. Hetero Labs Limited Unit V, No. 2:25-cv-11924 (D.N.J. filed Feb. 20, 2025). [2] U.S. Patent No. 8,642,626.